A Phase 2, Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients
This study is to evaluate the safety, efficacy and pharmacokinetics profile of human monoclonal antibodies, BRII-196 and BRII-198 compared with placebo in patients with COVID-19.
100 Clinical Results associated with Brii Biosciences, Inc.
0 Patents (Medical) associated with Brii Biosciences, Inc.
100 Deals associated with Brii Biosciences, Inc.
100 Translational Medicine associated with Brii Biosciences, Inc.